Inovio Pharmaceuticals (NASDAQ:INO)On August 10, 2015 shares of Inovio were up about 25% after the company announced a partnership deal with a big pharmaceutical company known as AstraZeneca (NYSE:AZN). Although one key thing to note here is that this deal is being established with MedImmune specifically, but it is the research and development arm for AstraZeneca. With this deal established AstraZeneca […]
Related ALXNYale University Is Bullish On ETFs & Alexion, Sold Twitter Last QuarterThe Dow Just Delayed A ‘Death Cross’The Vetr community has upgraded $ALXN to 4.5-Stars.(Vetr)Related CELGThe Historical Correlation Between Biotech Stocks And Interest Rates5 Biotechs With Catalysts Coming This WeekWeak Market? Don’t Tell That To Google, Celgene(Investor’s Business Daily)By and large, the number of shares short in the leading […]
Many individual investors have opted to invest in biotech ETFs and mutual funds. The XBI and SBIO funds have performed well because they focus more on small and mid-sized biotech companies. The IBB, which has emerged as something of a proxy for the industry for many investors, is weighted much more heavily to bigger, more proven biotech companies.The volatility of […]
The Dow Jones has been zigzagging nearly all year long. Everyone knows that.Transportation stocks, basic materials and commodities have been sagging, even plunging. Most people know that, too.What many people may not be aware of — or may be underestimating — is the strength and sustainability of one key sector that’s been making investors money through thick and thin: health […]
Several major biotech companies like Biogen (BIIB – Analyst Report), AbbVie (ABBV – Analyst Report), Celgene and Gilead reported second quarter results over the last five trading days. Biogen has been grabbing headlines for the wrong reasons – although the company’s earnings were better-than-expected, revenues missed expectations.With the company saying that it is cutting its outlook based on revised expectations […]
Anacor Pharmaceuticals (NASDAQ:ANAC)On Monday July 13, 2015 shares of Anacor went up 55%, closing around $131.93 per share after the company announced positive phase 3 results in patients who have atopic dermatitis. There were two phase 3 trials that were testing Anacor’s drug, Crisaborole, for these patients with atopic dermatitis — also known as Eczema. The company wanted to see […]
Submitted by Joseph Calhoun via Alhambra Investment Partners,
All that we see or seem is but a dream within a dream.
Edgar Allan Poe
All things are subject to interpretation. Whichever interpretation prevails at a given time is a function of power not truth.
I was walking down the street wearing glasses when the prescription ran out.
I think one of the hardest […]
The first half of 2015 has come and gone, and the long-running global bull market has significantly faltered.The Dow Jones Industrial Average fell 1.4% through the first six months of 2015, the first time the index has lost ground in that time frame since 2010. The S&P 500 eked out a 0.2% gain in the first half, its smallest H1 […]
The Celgene Corporation (CELG – Analyst Report) – Juno Therapeutics’ (JUNO – Analyst Report) immunotherapy deal worth at least a billion dollars was the main story in the biotech sector this week. While concerns are being raised about the high price tag, the deal just goes to show the growing interest in the field of immunotherapy. Meanwhile, quite a few […]
Hopes of Greece and its creditors reaching a deal later this week helped benchmarks end higher on Monday. Greece has submitted new fiscal proposals to avert a default. Separately, the Nasdaq closed at an all-time high lifted by gains in biotech stocks.For a look at the issues currently facing the markets, make sure to read today’s Ahead of Wall Street […]